DVx Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥50 | 0.0% |
| 2024 | ¥50 | +66.7% |
| 2023 | ¥30 | +20.0% |
| 2022 | ¥25 | +4.2% |
| 2021 | ¥24 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥47,484M | ¥45,851M | ¥50,322M | ¥55,989M |
| Gross Profit | ¥5,456M | ¥4,765M | ¥4,994M | ¥5,365M |
| Operating Income | ¥1,341M | ¥653M | ¥537M | ¥294M |
| Pretax Income | ¥1,351M | ¥376M | ¥538M | ¥303M |
| Net Income | ¥936M | ¥173M | ¥410M | ¥225M |
| EPS | ¥90.04 | ¥16.58 | ¥39.20 | ¥24.39 |
| Operating Margin | 2.82% | 1.42% | 1.07% | 0.53% |
| Balance Sheet | ||||
| Total Assets | ¥23,590M | ¥22,679M | ¥25,537M | ¥25,000M |
| Total Equity | ¥9,312M | ¥9,199M | ¥9,128M | ¥8,843M |
| Total Liabilities | ¥14,278M | ¥13,480M | ¥16,410M | ¥16,157M |
| Cash | ¥8,614M | ¥7,489M | ¥5,059M | ¥4,316M |
| Interest-bearing Debt | ¥10M | ¥13M | ¥13M | ¥19M |
| Equity Ratio | 39.47% | 40.56% | 35.74% | 35.37% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥1,485M | -¥423M | ¥726M | -¥1,274M |
| Investing CF | -¥477M | -¥397M | -¥632M | -¥919M |
| Financing CF | -¥245M | -¥312M | -¥524M | -¥551M |
| Free CF | ¥1,234M | -¥719M | ¥394M | -¥1,812M |
| Efficiency | ||||
| ROE | 10.05% | 1.88% | 4.49% | 2.55% |
| ROA | 3.97% | 0.76% | 1.61% | 0.90% |
Latest IR Information
-
Notice Regarding Cancellation of Treasury Stock
Under a share exchange agreement, Orba Healthcare Holdings is scheduled to acquire the company's issued shares. The board resolved to cancel all treasury stock immediately prior to the reference time. Cancellation date planned for September 1, 2026; current treasury stock...
Read more -
[DeVX] Withdrawal of Earnings Forecast for Fiscal Year Ending July 2026 | July 31, 2026
The company announced the withdrawal of its consolidated earnings forecasts for the second quarter (cumulative) and full year of the fiscal year ending March 2027. This is a measure due to the scheduled delisting of shares in August 2026.
Read more -
Q1 FY2027 Financial Results Summary (Consolidated)
The consolidated net sales for the first quarter of FY2027 are JPY 15,088 million, an increase of 9.6% YoY. Operating profit is JPY 2,805 million, and net profit is JPY 6,691 million, both showing increases. Segments such as arrhythmia and...
Read more -
【DeVX】Dividend Forecast Withdrawn｜Fiscal Year Ending March 2027
DeVX has withdrawn its dividend forecast for the fiscal year ending March 2027 due to the scheduled delisting resulting from a share exchange.
Read more -
Matters Concerning Controlling Shareholders, Etc.
Read more
Latest News (5 items)
Company Information
About
DVx Inc. engages in the research and development, design, purchasing/selling, import/export, repair, maintenance and inspection, and rental of medical devices and related peripheral devices in Japan. The company offers arrhythmia-related products, such as cardiac pacemakers, implantable cardioverter defibrillators, electrode catheters, and ablation catheters; ischemia-related products, that includes RAQUOS and resolution/resolution SD; and EPS Trainer, an intracardiac electrograms simulator; and wonder belt products. The company also engages in the design, manufacture, and purchasing/selling of medical computers; manufacture, purchasing/selling, repair, maintenance and inspection, rental, leasing, and import/export of medicines, quasi drugs, cosmetics, health foods, daily goods, nursing care products, and nursing care equipment; provision of internal and external medical and medical device-related general consulting and services, as well as medical publishing and market research services; and sale and purchase of second hand goods. The company was incorporated in 1986 and is headquartered in Tokyo, Japan.
